Astellas Taps Proteostasis In Potential $1.2bn Alliance

Assuming all milestones are met and options exercised, a new deal with Japan's Astellas will provide a bonanza for Proteostasis, being worth potentially more than $1.2 billion to the privately held U.S. drug discovery venture.